These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 37528088)

  • 1. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel.
    Raje N; Anderson K; Einsele H; Efebera Y; Gay F; Hammond SP; Lesokhin AM; Lonial S; Ludwig H; Moreau P; Patel K; Ramasamy K; Mateos MV
    Blood Cancer J; 2023 Aug; 13(1):116. PubMed ID: 37528088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC-1 study.
    Nooka AK; Rodriguez C; Mateos MV; Manier S; Chastain K; Banerjee A; Kobos R; Qi K; Verona R; Doyle M; Martin TG; van de Donk NWCJ
    Cancer; 2024 Mar; 130(6):886-900. PubMed ID: 37960969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis.
    Mazahreh F; Mazahreh L; Schinke C; Thanendrarajan S; Zangari M; Shaughnessy JD; Zhan F; van Rhee F; Al Hadidi S
    Blood Adv; 2023 Jul; 7(13):3069-3074. PubMed ID: 36857755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap.
    Longhitano AP; Slavin MA; Harrison SJ; Teh BW
    Blood Rev; 2021 Sep; 49():100810. PubMed ID: 33676765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective study.
    Jourdes A; Cellerin E; Touzeau C; Harel S; Denis B; Escure G; Faure E; Jamard S; Danion F; Sonntag C; Ader F; Karlin L; Soueges S; Cazelles C; de La Porte des Vaux C; Frenzel L; Lanternier F; Brousse X; Cazaubiel T; Berger P; Collignon A; Blot M; Pieragostini A; Charles M; Chaleteix C; Redor A; Roland V; Cartau T; Macro M; Chalopin T; Vallet N; Perrot A; Martin-Blondel G;
    Clin Microbiol Infect; 2024 Jun; 30(6):764-771. PubMed ID: 38432433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Position statement on infection screening, prophylaxis, and vaccination in pediatric patients with rheumatic diseases and immunosuppressive therapies, part 2: infection prophylaxis.
    Clemente Garulo D; Núñez-Cuadros E; Camacho Lovillo M; Calzada-Hernández J; Guillén Martín S; Fernández Silveira L; Lirola Cruz MJ; Tagarro A; Alcobendas Rueda RM; López López A; Satrustegi Aritziturri M; Calvo C
    Eur J Pediatr; 2023 Sep; 182(9):4271-4284. PubMed ID: 37439850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies.
    Lancman G; Parsa K; Kotlarz K; Avery L; Lurie A; Lieberman-Cribbin A; Cho HJ; Parekh SS; Richard S; Richter J; Rodriguez C; Rossi A; Sanchez LJ; Thibaud S; Jagannath S; Chari A
    Blood Cancer Discov; 2023 Nov; 4(6):440-451. PubMed ID: 37769148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
    Ludwig H; Terpos E; van de Donk N; Mateos MV; Moreau P; Dimopoulos MA; Delforge M; Rodriguez-Otero P; San-Miguel J; Yong K; Gay F; Einsele H; Mina R; Caers J; Driessen C; Musto P; Zweegman S; Engelhardt M; Cook G; Weisel K; Broijl A; Beksac M; Bila J; Schjesvold F; Cavo M; Hajek R; Touzeau C; Boccadoro M; Sonneveld P
    Lancet Oncol; 2023 Jun; 24(6):e255-e269. PubMed ID: 37269857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52).
    Mikulska M; Lanini S; Gudiol C; Drgona L; Ippolito G; Fernández-Ruiz M; Salzberger B
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S71-S82. PubMed ID: 29447988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations.
    Girmenia C; Cavo M; Offidani M; Scaglione F; Corso A; Di Raimondo F; Musto P; Petrucci MT; Barosi G
    Blood Rev; 2019 Mar; 34():84-94. PubMed ID: 30683446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy.
    Crombie JL; Graff T; Falchi L; Karimi YH; Bannerji R; Nastoupil L; Thieblemont C; Ursu R; Bartlett N; Nachar V; Weiss J; Osterson J; Patel K; Brody J; Abramson JS; Lunning M; Shah NN; Ayed A; Kamdar M; Parsons B; Caimi P; Flinn I; Herrera A; Sharman J; McKenna M; Armand P; Kahl B; Smith S; Zelenetz A; Budde LE; Hutchings M; Phillips T; Dickinson M
    Blood; 2024 Apr; 143(16):1565-1575. PubMed ID: 38252906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients.
    König C; Kleber M; Reinhardt H; Knop S; Wäsch R; Engelhardt M
    Ann Hematol; 2014 Mar; 93(3):479-84. PubMed ID: 24318541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell redirecting bispecific antibodies in multiple myeloma: Current landscape and future directions.
    O'Neill C; van de Donk NWCJ
    EJHaem; 2023 Aug; 4(3):811-822. PubMed ID: 37601851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature.
    Khattak ZE; Hashmi H; Khan SI; Aamir S; Arif U; Khan AI; Darwin A; Singh AD; Khouri J; Anwer F
    Ann Hematol; 2021 Sep; 100(9):2155-2172. PubMed ID: 34318356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors).
    Redelman-Sidi G; Michielin O; Cervera C; Ribi C; Aguado JM; Fernández-Ruiz M; Manuel O
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2(Suppl 2):S95-S107. PubMed ID: 29427804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group.
    Raje NS; Anaissie E; Kumar SK; Lonial S; Martin T; Gertz MA; Krishnan A; Hari P; Ludwig H; O'Donnell E; Yee A; Kaufman JL; Cohen AD; Garderet L; Wechalekar AF; Terpos E; Khatry N; Niesvizky R; Yi Q; Joshua DE; Saikia T; Leung N; Engelhardt M; Mothy M; Branagan A; Chari A; Reiman AJ; Lipe B; Richter J; Rajkumar SV; Miguel JS; Anderson KC; Stadtmauer EA; Prabhala RH; McCarthy PL; Munshi NC
    Lancet Haematol; 2022 Feb; 9(2):e143-e161. PubMed ID: 35114152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update.
    Taplitz RA; Kennedy EB; Bow EJ; Crews J; Gleason C; Hawley DK; Langston AA; Nastoupil LJ; Rajotte M; Rolston KV; Strasfeld L; Flowers CR
    J Clin Oncol; 2018 Oct; 36(30):3043-3054. PubMed ID: 30179565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Agents targeting lymphoid or myeloid cells surface antigens [II]: CD22, CD30, CD33, CD38, CD40, SLAMF-7 and CCR4).
    Drgona L; Gudiol C; Lanini S; Salzberger B; Ippolito G; Mikulska M
    Clin Microbiol Infect; 2018 Jun; 24 Suppl 2():S83-S94. PubMed ID: 29572070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Executive summary of consensus clinical practice guidelines for the prevention of infection in patients with multiple myeloma.
    Teh BW; Reynolds G; Slavin MA; Cooley L; Roberts M; Liu E; Thursky K; Talaulikar D; Mollee P; Szabo F; Ward C; Chan H; Prince HM; Harrison SJ;
    Intern Med J; 2023 Aug; 53(8):1469-1477. PubMed ID: 37093163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.